Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0027 | 0.3135 | 0.3135 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.3135 | 0.2319 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.002 | 0.1062 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 0.1062 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.002 | 0.1062 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.002 | 0.1062 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.002 | 0.1062 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.3135 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.002 | 0.1062 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.002 | 0.1062 | 0.1062 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.3135 | 0.2319 |
Mycobacterium ulcerans | DNA polymerase IV | 0.002 | 0.1062 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0027 | 0.3135 | 0.2319 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0033 | 0.533 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0033 | 0.533 | 0.4775 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.3135 | 0.2319 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0027 | 0.3135 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0033 | 0.533 | 0.4775 |
Giardia lamblia | DINP protein human, muc B family | 0.002 | 0.1062 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0.3135 | 0.2319 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.3135 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.